A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 28, Issue 3, 2001, Pages 211-230

  Huitema, A D R ^a,b   Mathot R A A ^a,b   Tibben, M M ^a   Rodenhuis, S ^c   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Autoinduction; Cyclophosphamide; Interaction; Pharmacokinetics; thioTEPA

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; PHOSPHORAMIDE MUSTARD; PRODRUG; THIOTEPA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INDUCTION; ENZYME INHIBITION; HYDROXYLATION; HYPOTHESIS; OXIDATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; NONLINEAR DYNAMICS; PHOSPHORAMIDE MUSTARDS; THIOTEPA;

EID: 0034954153     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011543508731     Document Type: Article

References (40)

1. High-dose chemotherapy for solid tumors
2. 359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation
3. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes
4. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
5. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
6. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
7. Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism
8. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation
9. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
10. Rapid development of enhanced clearance after high-dose cyclophosphamide
11. Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients
12. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors
13. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosurea
14. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: Exposure to activated metabolites
15. Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (thioTEPA)
16. A search for new metabolites of thioTEPA
17. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence-dependency in high-dose chemotherapy regimens
18. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy
19. Feasibility of multiple courses of high-dose cyclophosphamide, thioTEPA, and carboplatin for breast cancer or germ cell cancer
20. Randomized trial of high-dose chemotherapy and haemopoeitic progenitor-cell support in operable breast cancer with extensive auxiliary lymph-node involvement
21. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thioTEPA
22. Sampling technique from central venous catheters proves critical for pharmacokinetic studies
23. Simultaneous determination of N,N′,N″-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites using capillary gas chromatography
24. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells
25. Simple and selective determination of the active cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
26. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients
27. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
28. Xpose - An S-PLUS based population pharmacokinetic - Pharmacodynamic model building aid for NONMEM
29. Inhibition and induction of cytochrome P450 and the clinical implications
30. Population-pharmacokinetics (PK) study of high-dose cyclophosphamide (CPP) in a program of high dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) transplantation in high risk (HR) breast cancer (BC) patients (PTS)
31. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
32. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxaxaphosphorines
33. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites
34. A pharmacodynamic approach to the estimate of carbamazepine autoinduction
35. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism
36. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition
37. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects
38. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism